Hemab Therapeutics Holdings, Inc. Common Stock
COAG
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.09B
Close$
$48.50
8.5% upsideHemab Therapeutics Holdings Common Stock Target Price Details
Target Price by Analysts
8.5% upsideHemab Therapeutics Holdings Common Stock Target Price Details$3.16
92.9% downside
Current Fair Value
92.9% downsideOvervalued by 92.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.09 Billion |
|---|---|
| Enterprise Value | $1.86 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.33 |
| Beta | 1.85 |
| Outstanding Shares | 30,111,000 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -34.23 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 2.98 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 120.52%▲ 120.52% |
|---|---|
| Total Invested | $1.33B |
| Investors Holding | 56▲ 56.00% |
ESG Score
No data
About Hemab Therapeutics Holdings, Inc. Common Stock
72 employees
CEO: Benny Sorensen Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience fo...